CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue:
Genetic testing	$ 777,549	$ 779,116	$ 1,454,717	$ 1,498,563
Other	21,886	17,749	22,603	17,787
Total revenue	799,435	796,865	1,477,320	1,516,350
Cost of revenue	393,122	438,464	769,333	796,053
Gross profit	406,313	358,401	707,987	720,297
Operating expenses:
Research and development	317,440	359,799	763,714	664,618
Selling, general and administrative	1,176,110	1,253,143	2,312,760	2,455,598
Amortization of intangibles	28,863	28,863	57,726	57,726
Total operating expenses	1,522,413	1,641,805	3,134,200	3,177,942
Loss from operations	(1,116,100)	(1,283,404)	(2,426,213)	(2,457,645)
Other income (expense):
Interest income	860	1,901	1,603	4,307
Interest expense	(114,594)	(89,130)	(219,930)	(177,281)
Gain on disposal of assets				4,275
Total other income (expense)	(113,734)	(87,229)	(218,327)	(168,699)
Loss from continuing operations before income taxes	(1,229,834)	(1,370,633)	(2,644,540)	(2,626,344)
Benefit for income taxes
Loss from continuing operations	(1,229,834)	(1,370,633)	(2,644,540)	(2,626,344)
Income from discontinued operations, net of income taxes		158,366		158,366
Net loss	$ (1,229,834)	$ (1,212,267)	$ (2,644,540)	$ (2,467,978)
Basic and diluted net loss per common share from:
Continuing operations	$ (0.03)	$ (0.04)	$ (0.07)	$ (0.07)
Discontinued operations		$ 0.01	$ 0.00	$ 0.00
Net loss	$ (0.03)	$ (0.03)	$ (0.07)	$ (0.07)
Weighted average common shares outstanding, basic and diluted	36,756,802	36,650,158	36,752,456	36,634,173